Discovery of Pyrazolopyrimidine Derivatives as Novel Dual Inhibitors of BTK and PI3K δ

Brahmam Pujala,[‡] Anil K. Agarwal,[‡] Sandip Middya,[§] Monali Banerjee,[§] Arjun Surya,[§] Anjan K. Nayak,[‡] Ashu Gupta,[‡] Sweta Khare,[‡] Rambabu Guguloth,[‡] Nitin A. Randive,[‡] Bharat U. Shinde,[‡] Anamika Thakur,[‡] Dhananjay I. Patel,[‡] Mohd. Raja,[‡] Michael J. Green,[†] Jennifer Alfaro,^{||} Patricio Avila,^{||} Felipe Pérez de Arce,^{||,⊥} Ramona G. Almirez,[†] Stacy Kanno,[†] Sebastián Bernales,[†] David T. Hung,[†] Sarvajit Chakravarty,[†] Emma McCullagh,[†] Kevin P. Quinn,[†] Roopa Rai,[†] and Son M. Pham^{*,†}

[†]Medivation, Inc., 525 Market Street, 36th Floor, San Francisco, California 94105, United States

[‡]Integral BioSciences, Pvt. Ltd., C-64, Hosiery Complex Phase II Extension, Noida, Uttar Pradesh 201306, India

[§]Curadev, Pvt. Ltd., B-87, Sector 83, Noida, Uttar Pradesh 201305, India

^{||}Fundación Ciencia y Vida, Avenida Zañartu 1482, Ñuñoa, Santiago 7780272, Chile

[⊥]Departamento de Ciencias Biológicas, Facultad de Ciencias Biológicas, Universidad Andrés Bello, Santiago 8370146, Chile

S Supporting Information

ABSTRACT: The aberrant activation of B-cells has been implicated in several types of cancers and hematological disorders. BTK and PI3K δ are kinases responsible for B-cell signal transduction, and inhibitors of these enzymes have demonstrated clinical benefit in certain types of lymphoma. Simultaneous inhibition of these pathways could result in more robust responses or overcome resistance as observed in single agent use. We report a series of novel compounds that have low nanomolar potency against both BTK and PI3K δ as well as acceptable PK properties that could be useful in the development of treatments against B-cell related diseases.

KEYWORDS: BTK, PI3K, p110 δ , inhibitor, B-cell, BCR, pyrazolopyrimidine

B-cell receptor (BCR) signaling is essential for normal B-cell development, proliferation, and survival.¹ Constitutive activation of the signaling pathway downstream of BCR is a hallmark of B-cell malignancies such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), follicular B-cell non-Hodgkin lymphoma (FL), small lymphocytic lymphoma (SLL), and diffuse large B-cell lymphoma (DLBCL).^{2,3} Inhibition of BCR signaling is used clinically to treat B-cell malignancies, and there are several intervention points in the downstream signaling pathway that are clinically relevant including LYN, SYK, BTK, and PI3K δ .^{3,4}

Bruton's tyrosine kinase (BTK) is a member of the TEC family of nonreceptor tyrosine kinases and is an upstream activator of multiple antiapoptotic signaling molecules and pathways, which include phosphoinositide 3-kinase (PI3K). PI3K constitutes a family of lipid kinases, which, like BTK, are involved in cellular signaling and control a broad number of cellular processes. The PI3K family comprises four isoforms, α , β , γ , and δ that catalyze the phosphorylation of phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-trisphosphate (PIP3), a key signaling molecule that impacts cellular growth, proliferation, chemotaxis, differentiation, and survival.

The approval of ibrutinib⁵ (formerly PCI-32765) and idelalisib⁶ (formerly GS-1101) by the US FDA between 2013 and 2014 demonstrated the therapeutic benefit of inhibiting BTK (ibrutinib) and PI3K δ (idelalisib) for the treatment of certain B-cell malignancies such as CLL and MCL. However, de Rooij et al. reported that roughly one-third of patients receiving ibrutinib for CLL and MCL show primary resistance.^{7–9} Moreover, it is expected that a percentage of responsive patients who receive prolonged treatment with ibrutinib will develop resistance due to mutations of BTK and phospholipase C γ 2 (PLC γ 2), the kinase immediately downstream of BTK.^{10,11} In contrast to ibrutinib, mechanisms for resistance to idelalisib are not as well understood.¹² Although both kinases regulate BCR signaling, they do so via parallel pathways,¹³ making combination therapy, either by codosing or with a dual agent, an attractive strategy for potentially achieving deeper durable responses as well as preventing resistance. Herein we report the discovery of

Received: September 7, 2016

Accepted: October 28, 2016

Published: October 28, 2016

reversible dual inhibitors of BTK and PI3K δ for the potential treatment of B-cell malignancies.

In 2010, the Shokat group at UCSF reported a series of PI3K δ/γ dual inhibitors, the most potent being SW13 (PI3K δ IC₅₀ = 0.7 nM; PI3K γ IC₅₀ = 33 nM).¹⁴ Recognizing the structural similarities between PCI-29732,¹⁵ a noncovalent analogue of ibrutinib (**1**, BTK IC₅₀ = 8.2 nM), and SW13 (**2**), Figure 1, we speculated that appropriately designed molecules could maintain reasonable affinity for PI3K δ while also demonstrating affinity for BTK.

Figure 1. Structural similarities between PCI-29732 and SW13.

Toward that end, PCI-29732 was docked (Figure 2A) and SW13 was overlaid (Figure 2B) onto the BTK binding pocket of

Figure 2. Docking of PCI-29732 (A) and an overlay of SW13 (B) to BTK (3GEN) using Glide. The bound ligand is removed for ease of viewing.

structure 3GEN,¹⁶ which has a pyrrolopyrimidine-containing ligand that is otherwise identical to PCI-29732. As expected, the docked pose of PCI-29732 makes the same important interactions as the cocrystallized ligand, namely, two hydrogen bonds with each hinge residue, Glu475 and Met477, as well as a pi–pi interaction with Phe540. The pose for SW13 was achieved by superimposing the pyrazolopyrimidine of SW13 on to the pyrrolopyrimidine of the 3GEN ligand. The cocrystallized ligand was then removed for ease of viewing. This perspective view allowed us to quickly assess that the large tolyl-quinazolinone of SW13 would need to be modified to something smaller that would fit in this part of the BTK pocket. Although the propeller-like conformation is favorable for selective binding to PI3K δ ,¹⁷ we decided to address selectivity within the PI3K family at a later time. With this in mind, our initial analogues were designed with the methylene group removed to obviate the propeller-like bend, and the bicyclic-group attached to N-1 of the pyrazolopyrimidine was simplified.

The analogues were prepared following the route in Scheme 1. Starting from iodide **3**,¹⁸ a Suzuki coupling¹⁹ with boronic acid **4**

Scheme 1^a

^aReagents and conditions: (a) 3-fluoro-5-methoxyphenylboronic acid (**4**), Na₂CO₃, Pd(PPh₃)₄, DMF, H₂O, 75 °C, 2 h, 32%; (b) i. NaH, DMF, 0 °C–RT, ii. R-OMs, 80 °C, 2 h, 5–50%; (c) 1 M BBr₃ in CH₂Cl₂, 0 °C, 18 h, 3–50%.

afforded pyrazolopyrimidine **5**, which was subsequently modified with several mesylates. Treatment of compounds **6–8** with BBr₃ in CH₂Cl₂ cleaved the methyl-groups to afford the desired compounds **9–11**.

To our satisfaction, **9–11** not only retained PI3K δ activity but also gained activity against BTK, Table 1. In our assay, SW13 (**2**)

Table 1. N-1 Pyrazolopyrimidine Modifications to Give Compounds **6–11**^a

No.	R	BTK (IC ₅₀ , nM)	PI3K δ (IC ₅₀ , nM)
2	NA	>10000	<0.5
6	2-indanyl	1970	2790
7	1-indanyl	584	1830
8	2-tetralinyl	891	1340
9	2-indanyl	67	8
10	1-indanyl	217	13
11	2-tetralinyl	86	9

^aCompounds **7**, **8**, **10**, and **11** were tested as racemates.

demonstrated subnanomolar inhibition of PI3K δ , which was in agreement with the value reported by Shokat, and no inhibition of BTK. Replacing the methylene-linked quinazolinone group of SW13 with a 2-indanyl in **9** increased BTK activity to 67 nM while maintaining single-digit nanomolar activity against PI3K δ . Although not as dramatic, similar results were observed for **10** and **11**. Interestingly, the corresponding methoxy-containing analogues **6–8** had significantly attenuated activity against both kinases compared to **9–11**, signifying that either the phenolic group was making important interactions with both targets or the methoxy group is sterically encumbered.

Having identified a scaffold that provided dual activity against both BTK and PI3K δ , we next turned our attention toward evaluating the C-3 aryl group. As outlined in Scheme 2, C-3 modifications were prepared by alkylating pyrazolopyrimidine **3** with indan-2-yl methanesulfonate (**12**). Suzuki coupling of the

Scheme 2^a

^aReagents and conditions: (a) i. NaH, DMF, 0 °C–RT, ii. **12**, 80 °C, 2 h, 51%; (b) Ar–B(OR)₂, Na₂CO₃, Pd(PPh₃)₄, DMF, H₂O, 75 °C, 2–3 h, 30–70%.

resulting 3-iodopyrazolopyrimidine, **13**, with various boronic acids provided compounds **14–21**.

Interestingly, removal of the fluoro-substituent had little effect on BTK affinity but attenuated PI3K δ activity as demonstrated by comparing **9** and **14**, Table 2. Replacing the fluoro-substituent

Table 2. C-3 Pyrazolopyrimidine Modifications to Give Compounds 14–21

No.	Ar	BTK (IC ₅₀ , nM)	PI3K δ (IC ₅₀ , nM)
14	3-OH-Ph	ND ^a	ND ^b
15	3-Cl-5-OH-Ph	142	4
16	4-F-5-OH-Ph	7	61
17	4-Cl-5-OH-Ph	14	33
18	4-Br-5-OH-Ph	12	8
19	3-OH-4-Me-Ph	43	172
20	3-OH-4-OMe-Ph	84	32
21	3,4-diF-5-OH-Ph	27	3

^aIC₅₀ not determined; inhibition of BTK was 66% at 100 nM **14**. ^bIC₅₀ not determined; inhibition of PI3K δ was 41% at 100 nM **14**.

with a chloro-substituent (**15**) maintained moderate BTK activity while low nanomolar activity against PI3K δ was restored, suggesting that substitution at the *meta*-position may be important for proper binding to PI3K δ . This was further demonstrated when the halo-substituent was moved to the *para*-position as in **16–17**. In these examples, the PI3K δ IC₅₀ increased roughly 8-fold, compared to their corresponding *meta*-substituted variants. To our surprise, the BTK IC₅₀ decreased nearly 10-fold in the same examples. These were our first analogues where the potency against BTK was greater than PI3K δ . Increasing the size of the *para*-substituent to bromo (**18**) maintained BTK activity while enhancing PI3K δ activity.

At this point, compound **18** was the most potent dual BTK, PI3K δ inhibitor we had made thus far. Replacing the *para*-bromo group with a methyl or methoxy group resulted in attenuated activity against both targets as observed in **19** and **20**, respectively. This was somewhat surprising for BTK as we predicted that a pocket that could accommodate the phenyl ether of PCI-29732 and the bromo group of **18** would be more than large enough to accept moderately sized substituents such as methyl or methoxy. This suggests that electronic effects on the aryl-ring may also contribute given that electron donating groups such as the methoxy group in **20** appear to be weaker BTK binders than the corresponding electron withdrawing groups. Furthermore, in the case of **20**, the disruption of an internal hydrogen bond between the hydroxy and methoxy groups would also decrease binding affinity. Substituting both the *meta*- and *para*-positions as in **21** affords a compound with good BTK activity and excellent activity against PI3K δ . Inspired by the *in vitro* potency, we quickly sought to evaluate our compounds *in vivo*. Selected compounds from our initial hits were administered to mice and their pharmacokinetic (PK) properties are summarized in Table 3.

Unfortunately, all of our initial compounds performed poorly in mouse PK studies. The results suggested that the compounds generally suffered from high clearance and poor bioavailability. Interestingly, **20** had markedly lower clearance and a longer oral half-life compared to the other examples. Appreciating that phenolic groups could have the propensity to form O-linked conjugates *in vivo*, we speculated whether the hydroxyl was a primary contributor to the high clearance. The results for **18** and **20** would appear to corroborate this as the relative size of the

Table 3. *In Vivo* Mouse Pharmacokinetic Properties^a of Initial Hits

No.	CL (L/h/kg)	V _z (L/kg)	AUC _{PO} (μ M·h)	PO <i>t</i> _{1/2} (h)	F (%)
9^b	5.10	6.01	0.177	3.1	2.2
15^b	9.36	11.5	0.033	0.60	0.8
16^b	7.29	5.45	0.211	0.80	3.7
18^c	3.82	5.90	0.213	2.3	6.9
20^b	1.87	6.56	2.37	6.3	11
21^b	9.25	12.1	0.073	0.95	1.7

^aWinNonlin noncompartmental analysis. ^bDosed 5 mg/kg IV and 15 mg/kg PO. ^cDosed 1 mg/kg IV and 5 mg/kg PO.

adjacent group could decrease the relative rate of bioconjugation. In an effort to elucidate the factors that contributed to our *in vivo* PK results, we tested the compounds in a series of *in vitro* metabolism studies for oxidation and glucuronidation stability, Table 4.

Table 4. *In Vitro* Metabolism Results of Initial Hits^a

No.	mLM (%)	mUGT (%)	hLM (%)	hUGT (%)
9	25	<1	67	1.3
18	53	13	66	5.2
20	14	12	52	7.0
21	78	5.1	75	3.7

^aPercent parent remaining (%) after 30 min.

The *in vitro* metabolism assays were performed with either mouse or human liver microsomes, which were supplemented with either NADPH to assess oxidative stability (mLM or hLM) or UDP-glucuronic acid to assess glucuronidation transferase stability (mUGT or hUGT). The results demonstrate high turnover of substrate and identify glucuronidation as a clearance pathway *in vitro* for compounds **9**, **18**, **20**, and **21**. Moreover, in mice, glucuronidation appeared to be the primary clearance pathway for compounds **9**, **18**, and **21** given that the levels of parent remaining were significantly higher under NADPH conditions compared to when UDP-glucuronic acid was added. In human liver microsomes, phase II metabolism appeared to be more significant than oxidative metabolism for all compounds tested.

Armed with this information we set out to improve on our initial hits with a directed effort to replace the problematic phenolic group. Following Scheme 2, we prepared a series of analogues in which the hydroxy-group was replaced with either a fluoro- or amino-group, Table 5. In comparison to **21**, trifluorophenyl-containing analogue, **22**, had significantly decreased inhibition of both enzymes; however, stability toward bioconjugation was significantly increased. This reaffirms the importance of the phenol with respect to BTK and PI3K δ affinity, while demonstrating its liability to PK properties. Compounds **23–25** had substituted anilines in place of the phenol. These compounds showed improvement in BTK inhibition but continued to lack significant activity against PI3K δ . When reviewing our initial SAR, we noticed that **20** had over a 5-fold improvement in PI3K δ IC₅₀ compared to **19**. This suggested to us that the methoxy-group was able to adopt a favorable conformation when binding to PI3K δ . We prepared cyclic amino-ether **26** in an effort to tie-back the methylene group and preclude bond rotation. Gratifyingly, we observed nearly a 3-fold improvement in PI3K δ inhibition with a moderate decrease in BTK inhibition and excellent stability toward UGT

Table 5. C-3 Pyrazolopyrimidine Optimizations

No.	Ar	BTK ^a (% Inh)	PI3K δ ^a (% Inh)	mUGT ^b (% R)
21	3,4-diF-5-OH-Ph	74	87	7.1
22	3,4,5-triF-Ph	21	21	85
23	3-NH ₂ -4-F-Ph	79	8.2	92
24	3-NH ₂ -4,5-diF-Ph	63	26	97
25	3-NH ₂ -4-OMe-Ph	72	14	89
26		57	40	98
27		52	53	91
28	6-indolyl	46	24	ND ^c
29	5-benzimidazolyl	9.6	78	90

^aKinase percent inhibition at 100 nM test article. ^bPercent (%R) parent remaining after 30 min. ^cPercent (%R) not determined.

activity. Adding a *meta*-fluoro-substituent afforded **27**, which further enhanced the PI3K δ inhibition while maintaining BTK inhibition and UGT stability. Compound **27** was our first nonphenol containing analogue that achieved dual-inhibition at or below IC₅₀ = 100 nM but more importantly demonstrated low levels of glucuronidation in our *in vitro* mouse UGT assay. The indole-containing analogue **28** had reduced PI3K δ affinity while the benzimidazole containing analogue **29** lost nearly all activity against BTK compared to **27**.

Having identified a potential substitute for the phenol, we next turned our attention toward improving the biochemical affinity against both BTK and PI3K δ . In a similar manner to Scheme 1, we prepared optimized compounds **30–33**, Table 6. Substituting the indane of **27** with a tetralin affords ($\pm$)-**30**. Compared to **27**, the larger ring had little effect on PI3K δ binding but diminished affinity for BTK. Adding a fluoro-substituent on the aryl portion of the indane reduced affinity for both enzymes even further as observed in compound ($\pm$)-**31**. Amino-substitutions such as in compounds **32** and **33** also had little effect on PI3K δ binding but now provided improved BTK results compared to the unsubstituted analogues **27** and **30**, respectively. Comparing docked poses of **27** and **32** suggested that the improvements in BTK binding were the result of an additional H-bond interaction with Asn484, Figure 3. Interestingly, both enantiomers of **32** exhibited excellent dual-inhibition of BTK and PI3K δ , whereas (+)-**33** had a 9-fold increase in BTK IC₅₀ compared to (–)-**33**.

We selected both enantiomers of **32** for additional biochemical profiling in an effort to distinguish between the two molecules, Table 7. In a lipid kinase panel consisting of the various PI3K isoforms, (–)-**32** was more selective than (+)-**32** when compared against PI3K δ . The opposite trend was observed for the two nonreceptor tyrosine kinases. When comparing against BTK, (+)-**32** was slightly more selective against BMX, nonreceptor tyrosine kinase, which is closely related to BTK,

Table 6. N-1 Pyrazolopyrimidine Optimizations

No.	R	BTK (IC ₅₀ , nM)	PI3K δ (IC ₅₀ , nM)
27	2-indanyl	104	35
($\pm$)- 30	2-tetralinyl	ND ^a	ND ^b
($\pm$)- 31	2-(5-F-indanyl)	ND ^c	ND ^d
(+)- 32	2-(5-NH ₂ -indanyl)	24	47
(–)- 32	2-(5-NH ₂ -indanyl)	32	16
(+)- 33	2-(7-NH ₂ -tetralinyl)	176	55
(–)- 33	2-(7-NH ₂ -tetralinyl)	19	72

^aIC₅₀ not determined; inhibition of BTK was 34% at 100 nM ($\pm$)-**30**.

^bIC₅₀ not determined; inhibition of PI3K δ was 52% at 100 nM ($\pm$)-**30**.

^cIC₅₀ not determined; inhibition of BTK was 6.6% at 100 nM ($\pm$)-**31**.

^dIC₅₀ not determined; inhibition of PI3K δ was 26% at 100 nM ($\pm$)-**31**.

Figure 3. Docked poses of **27** (A) and **32** (B) with BTK indicate that **32** makes an additional H-bond interaction with Asn484.

and TEC versus (–)-**32**. In general, both compounds performed similarly in our full metabolism panel, which included rat (rLM) and dog (dLM) liver microsomes. The only clear distinction was that (+)-**32** appeared to be more stable than (–)-**32** to oxidative metabolism in mouse and dog liver microsomes. More importantly, these analogues showed good stability in the low affinity albeit high capacity glucuronidation assay. Lastly, both enantiomers were equal in regards to P-gp efflux potential on Caco-2 cells and mouse plasma protein binding.

Although both compounds appear to be more stable in rats, as well as dogs, we chose to continue our studies in mice. First, we wanted to determine the extent of our optimizations in comparison to our previous analogues tested for mouse PK. Second, we were anticipating that mice would be the primary species for our preclinical *in vivo* efficacy models. Table 8 summarizes the mouse PK properties for (+)-**32** and (–)-**32**. Compared to our initial leads, both compounds exhibited lower systemic clearance, which may largely be due to their improved stability against glucuronidation. Moreover, oral exposures increased over 125-fold for both compounds compared to **21**, resulting in oral bioavailabilities of 57% and 40% for (+)-**32** and (–)-**32**, respectively.

We were pleased to observe that the systematic optimizations starting from SW13 and our initial hits resulted in a set of

Table 7. Biochemical and *in Vitro* ADME Results for (+)-32 and (–)-32

No.	kinase selectivity (ratio)					<i>in vitro</i> metabolism ^d (%R)						Caco-2 ^e	PPB ^f (%)
	PI3K α ^a	PI3K β ^a	PI3K γ ^a	BMX ^b	TEC ^c	hLM	mLM	rLM	dLM	hUGT	mUGT		
(+)-32	6	34	2	4	20	71	28	45	65	91	93	1.3	98
(-)-32	17	44	7	1	7	63	11	46	32	91	99	1.7	98

^aRatio of PI3K IC₅₀/PI3K δ IC₅₀. ^bRatio of BMX IC₅₀/BTK IC₅₀. ^cRatio of TEC IC₅₀/BTK IC₅₀. ^dPercent parent remaining (%R) after 30 min.

^eEfflux ratio, P_{app}B → A/P_{app}A → B. ^fPercent mouse plasma protein binding (PPB).

Table 8. *In Vivo* Mouse Pharmacokinetic Properties^a of 32^b

No.	CL (L/h/kg)	V _z (L/kg)	AUC _{PO} (μM·h)	PO t _{1/2} (h)	F (%)
(+)-32	1.46	0.58	9.28	1.2	57
(–)-32	0.59	3.44	15.2	1.3	40

^aWinNonlin noncompartmental analysis. ^bDosed 2 mg/kg IV and 10 mg/kg PO.

compounds that are (1) potent dual-inhibitors of BTK and PI3K δ and (2) have improved mouse PK properties. These compounds will serve as the starting point for a subsequent round of optimizations, which will include cellular and *in vivo* proof-of-concept (PoC) studies.

■ ASSOCIATED CONTENT

■ Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acsmchemlett.6b00356.

Experimental procedures and analytical data for 3, 5–33; descriptions for *in vitro* biochemical and metabolic stability assays; descriptions for *in vivo* PK experiments; description for molecular modeling (PDF)

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: son.pham@medivation.com.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

The authors would like to thank Anup Barde, Vijay Sharma, Shailender Chauhan, Abhinandan Danodia, Kailas Thube, and Ankesh Sharma for their help with the scale-up of key intermediates; Diksha Sharma, Vishal Budha, and Rahul Takalkar for their assistance in the purification of intermediates and final compounds; and Shivam Dixit and Meena Bisht for their assistance in acquiring NMR data. We also thank Christopher Higgs for his analysis and comments regarding the preparation of this manuscript. This research was funded solely by Medivation, Inc.

■ ABBREVIATIONS

AUC_{po}, area under the concentration–time curve from time zero to the last quantifiable concentration after oral (PO) administration; BCR, B-cell receptor; BMX, bone marrow kinase on chromosome X; CL, total body clearance after intravenous (IV) administration; F, absolute oral bioavailability determined from AUC_{po}/AUC_{iv} × dose_{iv}/dose_{po}; HP β CD, 2-hydroxypropyl- β -cyclodextrin; LM, liver microsomes; LYN, Lck/Yes novel tyrosine kinase; ND, not determined; PEG, polyethylene glycol; PO t_{1/2}, terminal half-life after oral administration; SYK, spleen tyrosine kinase; TEC, tyrosine-protein kinase Tec; UGT, uridine

5'-diphospho-glucuronosyltransferase; V_z, total volume of distribution after IV administration

■ REFERENCES

- (1) Niiri, H.; Clark, E. A. Regulation of B-Cell Fate by Antigen-Receptor Signals. *Nat. Rev. Immunol.* **2002**, *2*, 945–956.
- (2) Seda, V.; Mraz, M. B-Cell Receptor Signalling and Its Crosstalk with Other Pathways in Normal and Malignant Cells. *Eur. J. Haematol.* **2015**, *94*, 193–205.
- (3) Rickert, R. C. New Insights into Pre-BCR and BCR Signalling with Relevance to B Cell Malignancies. *Nat. Rev. Immunol.* **2013**, *13*, 578–591.
- (4) Mato, A.; Jauhari, S.; Schuster, S. J. Management of Chronic Lymphocytic Leukemia (CLL) in the Era of B-Cell Receptor Signal Transduction Inhibitors. *Am. J. Hematol.* **2015**, *90*, 657–664.
- (5) Cameron, F.; Sanford, M. Ibrutinib: First Global Approval. *Drugs* **2014**, *74*, 263–271.
- (6) Miller, B. W.; Przepiorka, D.; de Claro, R. A.; Lee, K.; Nie, L.; Simpson, N.; Gudi, R.; Saber, H.; Shord, S.; Bullock, J.; Marathe, D.; Mehrotra, N.; Hsieh, L. S.; Ghosh, D.; Brown, J.; Kane, R. C.; Justice, R.; Kaminskas, E.; Farrell, A. T.; Pazdur, R. FDA Approval: Idelalisib Monotherapy for the Treatment of Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma. *Clin. Cancer Res.* **2015**, *21*, 1525–1529.
- (7) De Rooij, M. F. M.; Kuil, A.; Kater, A. P.; Kersten, M. J.; Pals, S. T.; Spaargaren, M. Ibrutinib and Idelalisib Synergistically Target BCR-Controlled Adhesion in MCL and CLL: A Rationale for Combination Therapy. *Blood* **2015**, *125*, 2306–2309.
- (8) Wang, M. L.; Rule, S.; Martin, P.; Goy, A.; Auer, R.; Kahl, B. S.; Jurczak, W.; Advani, R. H.; Romaguera, J. E.; Williams, M. E.; Barrientos, J. C.; Chmielowska, E.; Radford, J.; Stilgenbauer, S.; Dreyling, M.; Jedrzejczak, W. W.; Johnson, P.; Spurgeon, S. E.; Li, L.; Zhang, L.; Newberry, K.; Ou, Z.; Cheng, N.; Fang, B.; McGreivy, J.; Clow, F.; Buggy, J. J.; Chang, B. Y.; Beaupre, D. M.; Kunkel, L. A.; Blum, K. A. Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma. *N. Engl. J. Med.* **2013**, *369*, 507–516.
- (9) Byrd, J. C.; Furman, R. R.; Coutre, S. E.; Flinn, I. W.; Burger, J. A.; Blum, K. A.; Grant, B.; Sharman, J. P.; Coleman, M.; Wierda, W. G.; Jones, J. A.; Zhao, W.; Heerema, N. A.; Johnson, A. J.; Sukbuntherng, J.; Chang, B. Y.; Clow, F.; Hedrick, E.; Buggy, J. J.; James, D. F.; O'Brien, S. Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia. *N. Engl. J. Med.* **2013**, *369*, 32–42.
- (10) Woyach, J. A.; Furman, R. R.; Liu, T.-M.; Ozer, H. G.; Zaparka, M.; Ruppert, A. S.; Xue, L.; Li, D. H.-H.; Steggerda, S. M.; Versele, M.; Dave, S. S.; Zhang, J.; Yilmaz, A. S.; Jaglowski, S. M.; Blum, K. A.; Lozanski, A.; Lozanski, G.; James, D. F.; Barrientos, J. C.; Lichter, P.; Stilgenbauer, S.; Buggy, J. J.; Chang, B. Y.; Johnson, A. J.; Byrd, J. C. Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib. *N. Engl. J. Med.* **2014**, *370*, 2286–2294.
- (11) Komarova, N. L.; Burger, J. A.; Wodarz, D. Evolution of Ibrutinib Resistance in Chronic Lymphocytic Leukemia (CLL). *Proc. Natl. Acad. Sci. U. S. A.* **2014**, *111*, 13906–13911.
- (12) Wiestner, A. The Role of B-Cell Receptor Inhibitors in the Treatment of Patients with Chronic Lymphocytic Leukemia. *Haematologica* **2015**, *100*, 1495–1507.
- (13) Suzuki, H.; Matsuda, S.; Terauchi, Y.; Fujiwara, M.; Ohteki, T.; Asano, T.; Behrens, T. W.; Kouro, T.; Takatsu, K.; Kadowaki, T.; Koyasu, S. PI3K and Btk Differentially Regulate B Cell Antigen

Receptor-Mediated Signal Transduction. *Nat. Immunol.* **2003**, *4*, 280–286.

(14) Williams, O.; Houseman, B. T.; Kunkel, E. J.; Aizenstein, B.; Hoffman, R.; Knight, Z. A.; Shokat, K. M. Discovery of Dual Inhibitors of the Immune Cell PI3Ks p110delta and p110gamma: A Prototype for New Anti-Inflammatory Drugs. *Chem. Biol.* **2010**, *17*, 123–134.

(15) Pan, Z.; Scheerens, H.; Li, S.-J.; Schultz, B. E.; Sprengeler, P. A.; Burrill, L. C.; Mendonca, R. V.; Sweeney, M. D.; Scott, K. C. K.; Grothaus, P. G.; Jeffery, D. A.; Spoerke, J. M.; Honigberg, L. A.; Young, P. R.; Dalrymple, S. A.; Palmer, J. T. Discovery of Selective Irreversible Inhibitors for Bruton's Tyrosine Kinase. *ChemMedChem* **2007**, *2*, 58–61.

(16) Marcotte, D. J.; Liu, Y.-T.; Arduini, R. M.; Hession, C. A.; Miatkowski, K.; Wildes, C. P.; Cullen, P. F.; Hong, V.; Hopkins, B. T.; Mertsching, E.; Jenkins, T. J.; Romanowski, M. J.; Baker, D. P.; Silvian, L. F. Structures of Human Bruton's Tyrosine Kinase in Active and Inactive Conformations Suggest a Mechanism of Activation for TEC Family Kinases. *Protein Sci.* **2010**, *19*, 429–439.

(17) Berndt, A.; Miller, S.; Williams, O.; Le, D. D.; Houseman, B. T.; Pacold, J. I.; Gorrec, F.; Hon, W.-C.; Liu, Y.; Rommel, C.; Gaillard, P.; Ruckle, T.; Schwarz, M. K.; Shokat, K. M.; Shaw, J. P.; Williams, R. L. The p110 Delta Structure: Mechanisms for Selectivity and Potency of New PI(3)K Inhibitors. *Nat. Chem. Biol.* **2010**, *6*, 117–124.

(18) Rai, R.; Chakravarty, S.; Green, M. J.; Pham, S. M.; Pujala, B.; Agarwal, A. K.; Nayak, A. K.; Khare, S.; Guguloth, R.; Randive, N. A. Preparation of pyrazolo[3,4-D]pyrimidines and Other Heterocyclic Compounds That Are Inhibitors of Both Btk and PI3K δ for Therapy of Cancer and Autoimmune Disorders. P.C.T. Int. Appl. No. WO2015058084A1, 2015.

(19) Suzuki, A. Organoboranes in Organic Syntheses Including Suzuki Coupling Reaction. *Heterocycles* **2010**, *80*, 15–43.